EUCTR2004-005037-19-ES进行中（未招募）不适用
Multicenter, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least One Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies - Dose-Ranging Study in HIV-Infected Patients With Documented Resistance to Antiretroviral Therapies
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a. Patient is HIV positive as determined by a positive ELISA and has screening plasma HIV RNA (determined by the central laboratory) >5,000 copies/mL within 35 days prior to the treatment phase of this study.
- •b.Patient has a screening CD4 cell count >50 cells/mm3 (determined by the central laboratory) within 35 days prior to the treatment phase of this study.
- •c.Patient is ART experienced and on stable ART for >3 months.
- •d.Patient has HIV with documented reduced susceptibility to at least one drug in each of the 3 classes of licensed oral ARTs (NNRTI + NRTI + PI) as per genotypic/phenotypic resistance report (PhenoSense GT) from the central laboratory.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a. Patient has used another experimental HIV-integrase inhibitor
- •b.Patient requires use of NNRTI (Efavirenz, Nevirapine, Delavirdine) in OBT
- •c.Patient has any condition or prestudy laboratory abnormality, or history of any illness, which, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs to the patient.
研究者
相似试验
进行中（未招募）
不适用
Multicenter, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least One Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies - Dose-Ranging Study in HIV-Infected Patients With Documented Resistance to Antiretroviral TherapiesEUCTR2004-005037-19-DEMerck & Co. Inc.200
进行中（未招募）
1 期
Multicenter, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least One Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies - Dose-Ranging Study in HIV-Infected Patients With Documented Resistance to Antiretroviral Therapiesnspecified human immunodeficiency virus [HIV] diseaseMedDRA version: 7.0Level: LLTClassification code 10020162EUCTR2004-005037-19-DKMerck Sharp & Dohme200
进行中（未招募）
1 期
Multicenter, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of Raltegravir in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least One Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies - Dose-Ranging Study in HIV-Infected Patients With Documented Resistance to Antiretroviral Therapiesnspecified human immunodeficiency virus [HIV] diseaseMedDRA version: 7.0Level: LLTClassification code 10020162EUCTR2004-005037-19-GBMerck Sharp & Dohme Limited
进行中（未招募）
不适用
Multicenter, Double Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiretroviral TherapiesEUCTR2004-005037-19-ITMSD ITALIA S.R.L.200
进行中（未招募）
不适用
A multicenter, multiple dose, double-blind, randomized, placebo-controlled, parallel group study of the safety and efficacy of AGN 203818 in female patients with fibromyalgia syndrome.Fibromyalgia syndrome in female patientsMedDRA version: 9.1Level: LLTClassification code 10016631Term: Fibromyalgia syndromeEUCTR2006-006100-11-DEAllergan Ltd160